Eastman Chemical Company
EMN
$67.09
+0.16%
Eastman Chemical Company is a global specialty chemical manufacturer operating in the Basic Materials sector, producing a diverse portfolio of materials, additives, and functional products for industries such as transportation, building & construction, and consumables. The company has strategically positioned itself as a focused player in higher-margin specialty chemicals after divesting non-core businesses. The current investor narrative is dominated by the company's transition through a cyclical downturn, as evidenced by recent quarterly revenue declines and margin compression, with debates centered on the timing and strength of a potential recovery in end-market demand and the execution of its specialty product portfolio strategy.…
EMN
Eastman Chemical Company
$67.09
EMN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eastman Chemical Company's 12-month outlook, with a consensus price target around $87.22 and implied upside of +30.0% versus the current price.
Average Target
$87.22
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$54 - $87
Analyst target range
Analyst coverage for EMN is moderate with 10 analysts providing estimates. The consensus sentiment appears mixed but leans cautiously optimistic, as evidenced by recent institutional actions including a 'Buy' from Citigroup and BofA Securities in February 2026, but also a downgrade from RBC Capital to 'Sector Perform' in January 2026. The average revenue estimate for the next period is $9.74 billion, with a tight range between $9.71B and $9.77B, indicating high conviction on the top-line forecast. The average EPS estimate is $7.75, with a low of $7.50 and a high of $8.05. The wide dispersion in target prices is not provided in the data, but the recent rating actions and the significant gap between trailing and forward P/E suggest analysts are debating the pace and magnitude of the company's recovery, leading to a range of outcomes. The limited number of analysts and the recent downgrade signal some caution, but the maintained 'Buy' or 'Overweight' ratings from several firms suggest a portion of the Street sees value at current levels if a cyclical rebound materializes.
Bulls vs Bears: EMN Investment Factors
The evidence currently tilts bearish due to the severe and ongoing fundamental deterioration in revenue and margins, which is the primary driver of the stock's deep underperformance. However, the bull case is compellingly framed by a deeply discounted valuation that prices in a significant recovery. The single most important tension in the investment debate is the timing and magnitude of the earnings rebound. Bears see the Q4 gross margin of 17.1% as evidence of a prolonged cyclical slump with no near-term catalyst, while bulls point to the forward P/E of 10.33x and analyst EPS target of $7.75 as proof the market has already discounted the worst and is set for a re-rating on any positive demand signal.
Bullish
- Deeply Discounted Forward Valuation: The forward P/E of 10.33x is a significant discount to the trailing P/E of 15.45x and far below the historical high of 38.37x, implying the market is pricing in a substantial earnings recovery. This low multiple, coupled with a Price/Sales ratio of 0.84x, suggests the stock is priced for a cyclical trough, offering a margin of safety if a recovery materializes.
- Analyst Confidence in Earnings Rebound: Analysts project a robust forward EPS of $7.75, a dramatic increase from the recent quarterly EPS of $0.92. The tight revenue estimate range ($9.71B-$9.77B) indicates high conviction in the top-line forecast, supporting the narrative of a predictable cyclical recovery from the current downturn.
- Strong Free Cash Flow Generation: The company generated $424 million in trailing-twelve-month free cash flow, demonstrating an ability to produce cash through the cycle. This provides financial flexibility to maintain its 5.2% dividend yield and navigate the current demand weakness without a liquidity crisis.
- Specialty Chemical Portfolio Focus: The company's strategic shift to higher-margin specialty products is a long-term positive, though currently masked by cyclical pressures. The historical gross margin of 24.8% in Q4 2024 versus the current 17.1% shows the operational leverage potential when demand recovers.
Bearish
- Severe Revenue & Margin Contraction: Q4 2025 revenue declined -12.1% YoY, and gross margin collapsed to 17.1% from 24.8% a year ago. This sequential deterioration from $2.29B in Q1 to $1.97B in Q4 shows deep end-market weakness, directly pressuring profitability as operating margin fell to 6.1% from 16.8%.
- Persistent Relative Underperformance: EMN has underperformed the SPY by -37.4% over the past year and -10.9% over the past month, indicating a consistent lack of investor confidence. The stock's beta of 1.057 means it has been more volatile than the market on the downside, amplifying losses during the sector sell-off.
- High Short Interest & Skepticism: A short ratio of 4.22 reflects significant market skepticism about a near-term recovery. This overhead supply of shares can cap rallies and indicates a portion of the market is betting the cyclical downturn will be deeper or longer than anticipated.
- Elevated Leverage in a Downturn: A debt-to-equity ratio of 0.85, while not extreme, adds financial risk during a period of compressed cash flow. The recent quarterly operating cash flow volatility, from negative $167M to positive $502M, raises concerns about the sustainability of cash generation to service debt and dividends.
EMN Technical Analysis
The stock is in a sustained downtrend over the past year, with a 1-year price change of -10.40%, significantly underperforming the SPY's +27.04% gain. As of the latest close at $72.42, the price is trading approximately 35% above its 52-week low of $56.11 but 13% below its 52-week high of $83.47, positioning it in the lower-middle of its annual range and suggesting it is not yet at a deep value extreme but has experienced substantial weakness. Recent short-term momentum shows conflicting signals; the stock is down -6.30% over the past month, indicating continued selling pressure, but is up +2.97% over the past three months, hinting at a potential stabilization or nascent recovery attempt after a sharp decline from the February peak near $81. The stock's beta of 1.057 indicates it is slightly more volatile than the broader market, which has contributed to its amplified underperformance during the recent sell-off. Key technical levels are clearly defined, with major resistance at the 52-week high of $83.47 and primary support at the 52-week low of $56.11. A breakout above the $80-81 area (the February highs) would signal a potential trend reversal, while a breakdown below the $68-$70 support zone (tested in late March and May) could open the path toward the 52-week low. The recent price action suggests the stock is consolidating after a significant correction, with high relative weakness versus the market.
Beta
1.07
1.07x market volatility
Max Drawdown
-31.6%
Largest decline past year
52-Week Range
$56-$83
Price range past year
Annual Return
-14.2%
Cumulative gain past year
| Period | EMN Return | S&P 500 |
|---|---|---|
| 1m | -11.1% | -1.7% |
| 3m | -10.6% | +13.7% |
| 6m | +4.3% | +9.2% |
| 1y | -14.2% | +20.7% |
| ytd | +4.3% | +9.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMN Fundamental Analysis
Eastman's revenue trajectory reflects a challenging environment, with Q4 2025 revenue of $1.97 billion representing a -12.1% year-over-year decline, continuing a trend of sequential quarterly revenue decreases from $2.29 billion in Q1 2025. This indicates a significant top-line contraction, primarily driven by weak end-market demand across its segments. Profitability has been pressured; while the company remains profitable with Q4 net income of $105 million, gross margin contracted sharply to 17.1% in Q4 from 24.8% in the year-ago quarter, and operating margin fell to 6.1% from 16.8%. The net margin of 5.3% in Q4, though positive, is down substantially from the 14.7% net margin reported in Q4 2024, highlighting severe margin compression. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.85, and liquidity is adequate with a current ratio of 1.37. However, free cash flow generation has been volatile; while trailing-twelve-month free cash flow is a positive $424 million, quarterly operating cash flow has fluctuated significantly, from a negative $167 million in Q1 2025 to a positive $502 million in Q4 2025. The ROE of 7.95% and ROA of 3.53% reflect diminished returns on capital amidst the current downturn.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$424000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMN Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 15.45x, while the forward P/E is notably lower at 10.33x, indicating the market expects a significant earnings recovery. This forward multiple is based on estimated EPS of $7.75 for the next period, a substantial increase from the most recent quarterly EPS of $0.92, implying strong anticipated profit growth. Compared to its own historical valuation, the current trailing P/E of 15.45x is below the multi-year range observed in the data, which has frequently been above 20x and even reached 38.37x in Q3 2025, suggesting the stock is trading at a discount to its historical average. The stock also trades at a Price/Sales ratio of 0.84x and an EV/Sales of 1.55x, which are relatively low multiples that may reflect the cyclical trough in earnings and margins. The forward earnings discount and depressed sales multiples point to a market pricing in a cyclical recovery, but with skepticism given the recent fundamental deterioration.
PE
15.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -27x~2433x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the continuation of severe margin compression, as evidenced by the Q4 gross margin of 17.1%, down 770 basis points year-over-year. This erosion directly impacts profitability, with net income falling to $105M from $330M in the prior-year quarter. The company's debt-to-equity of 0.85, while manageable, becomes a heavier burden if free cash flow generation remains volatile; quarterly operating cash flow swung from -$167M to +$502M, indicating unpredictability. Furthermore, the high payout ratio of 80% suggests the 5.2% dividend yield could be at risk if earnings do not recover as anticipated.
Market & Competitive Risks: EMN trades at a forward P/E of 10.33x, a discount to its historical average, but this discount reflects skepticism about its recovery trajectory. The stock's beta of 1.057 means it is slightly more volatile than the market, which has contributed to its significant underperformance (down -10.4% vs. SPY +27.04% over one year). A key risk is valuation compression persisting if the anticipated cyclical rebound in end-markets like transportation and construction is delayed further. Competitive pressures and potential global economic slowdowns could prolong the downturn, preventing the margin recovery embedded in forward estimates.
Worst-Case Scenario: The worst-case scenario involves a deeper, more protracted cyclical downturn where Q4 2025's weak demand and margin profile become the new normal, not a trough. This would lead to analyst EPS estimates being cut, eliminating the forward valuation support. In this scenario, the stock could re-test its 52-week low of $56.11, representing a downside of approximately -22.5% from the current price of $72.42. A breakdown below that level could trigger a further decline toward the $50 range, especially if the dividend is cut due to unsustainable payout levels, leading to a total potential loss of -30% or more from current levels.